# RGNX — Regenxbio Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** RGNX  
**Sources:** 29  
**Published:** 2026-10-30  
**Canonical:** https://app.k3vl4r.com/research/deep-research-rgnx-regenxbio-inc-catalysts-narrative-risks-10133

---

# REGENXBIO Inc. (RGNX) — Research Snapshot as of October 30, 2026

## Market Context
RGNX trades on Nasdaq with a market capitalization of roughly $478M, near the low end of its 52-week range ($5.45–$16.19), and carries a beta of ~1.13, reflecting its high-volatility biotech profile [[13]](https://www.marketbeat.com/earnings/reports/2026-11-5-regenxbio-inc-stock/), [[25]](https://finance.yahoo.com/quote/RGNX/). The stock fell roughly 14% in a single week in late October, and there was noted lack of market enthusiasm ahead of upcoming events [[28]](https://stocktwits.com/symbol/RGNX).

## Recent Catalysts (last ~1–3 months)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-rgnx-regenxbio-inc-catalysts-narrative-risks-10133 (free to sign up)._